IOR-160

Overview

IOR-160 is a dual inhibitor of casein kinase 2 ( CK2 ) and HDACs . IOR-160 exhibits high selectivity for CK2 ( IC 50 = 1.7 nM) and broad inhibitory activity against HDAC ( HDAC 1, 2, 3, and 6 with IC 50 s of 3.3 nM, 24.0 nM, 3.9 nM, and 13.0 nM, respectively, with low activity for HDAC8 ). IOR-160 modulates key cellular signaling pathways by inhibiting AKT phosphorylation and increasing acetylated α-tubulin. IOR-160 inhibits tumor growth and reduces tumor burden through dual CK2/HDAC inhibition. IOR-160 is indicated for use in triple-negative breast cancer research.

Application

Products | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Signaling Pathways > Casein Kinase | Products > Signaling Pathways > HDAC

Product Information

• Catalog No.: HY-176561
• CAS No.: 2421119-78-8
• Molecular Formula: C23H25F3N4O6
• Molecular Weight: 510.46
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source